Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK3368715 is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50s: 3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). It has strong anti-cancer activity.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約10-14 週間 | ¥ 624,500 |
50 mg | 約10-14 週間 | ¥ 822,000 |
100 mg | 約10-14 週間 | ¥ 1,124,500 |
ターゲット&IC50 | PRMT8:1.7 nM , PRMT4:1148 nM , PRMT1:3.1 nM , PRMT6:5.7 nM , PRMT3:48 nM |
In vivo | GSK3368715 markedly impacts the growth of BxPC3 xenografts across all examined doses, achieving a reduction in tumor growth of 78% and 97% for the 150 mg/kg and 300 mg/kg dose groups, respectively. |
別名 | EPZ019997 |
分子量 | 366.54 |
分子式 | C20H38N4O2 |
CAS No. | 1629013-22-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GSK3368715 1629013-22-4 Chromatin/Epigenetic Histone Methyltransferase EPZ 019997 GSK-3368715 EPZ019997 EPZ-019997 GSK 3368715 Inhibitor inhibitor inhibit